It has been suggested that GastroPanel might be a useful tool for the diagnosis of chronic atrophic gastritis measuring 4 biomarkers in blood, including basal gastrin-17 (G17), pepsinogen I and II (PGI and PGII), and Helicobacter pylori antibodies.
Dr Adrian McNicholl and colleagues determined the accuracy of GastroPanel for the diagnosis of chronic atrophic gastritis.
The researchers performed a prospective, blinded, multicenter study that included dyspeptic patients.
G17, PGI, and PGII were determined by enzyme immunoassays.
The team obtained 3 antrum, and 2 corpus biopsies for standard histological analysis and rapid urease test.
|The negative predictive value was 92%|
|European Journal of Gastroenterology & Hepatology|
Biopsies were analyzed by a single blinded expert pathologist.
The research team evaluated 91 patients.
G17 was reduced in patients with antrum chronic atrophic gastritis, and increased in patients with corpus chronic atrophic gastritis, but its accuracy was only acceptable in the case of corpus localization.
The team found that PGII difference was almost statistically significant only when testing for corpus atrophy.
The researchers found that the PGI and PGI/PGII ratio showed no significant differences.
The team observed that Helicobacter pylori antibody levels were higher in H. pylori-infected patients.
The accuracy of GastroPanel for the diagnosis of chronic atrophic gastritis.
For GastroPanel, the sensitivity was 50%, and specificity was 80%.
The positive and negative predictive values were 25% and 92%, respectively, with positive and negative likelihood ratios of 2.4 and 0.6, respectively.
Dr McNicholl's team concludes, "GastroPanel is not accurate enough for the diagnosis of chronic atrophic gastritis."
"Thus, its systematic use in clinical practice cannot be recommended."